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Letter to the Editor
Dear Sir:
Stroke is the leading cause of long-term adult disability 
throughout the world.1 Even with rehabilitation by physiotherapy 
and occupational therapy, about half of all stroke survivors are 
disabled with significant functional impairment. Thus, novel re-
habilitation strategies are needed to supplement conventional 
therapies. An innovative herbal formula based on Traditional 
Chinese Medicine (TCM) literature for post-stroke rehabilitation 
using Huangqi (Radix Astragali, Inner Mongolia, 30g), Chuanx-
iong (Rhizoma Chuanxiong, Sichuan, 6g), Danshen (Radix Salviae 
Miltorrhizae, Sichuan, 20g), Juemingzi (Cassia Obtusifolia Linne, 
Jiangsu, 15g), Gancao (Radix Glycyrrhizae, Xinjiang, 6g), Danggui 
(Radix Angelicae Sinensiss, Gansu, 6g), Chishao (Paeoniae 
Veitchii Radix, Inner Mongolia, 15g) was demonstrated to be 
able to reduce the post-stroke brain damage by increasing the 
anti-oxidative status in vivo and in vitro rat model with transient 
middle cerebral artery occlusion.2 However, the protective effects 
of this formula on post-stroke recovery in humans remain un-
known. We therefore conducted a randomized, double-blinded, 
placebo-controlled clinical trial to explore the potential efficacy 
and safety of this herbal formula in post-stroke rehabilitation.
This pilot study was conducted in 6 general hospitals with 
acute stroke admission in Hong Kong between 2006 and 2010, 
with ethics committee approval and written informed consent 
received at all participating centers. Inclusion criteria were: age ≥18 
years; diagnosis of ischemic stroke defined by the World Health 
Organization definition; previously independent in activities of 
daily living with a Barthel Index3 of 90 or more; a modified 
Rankin scale (mRS)4 of 0 or 1 before admission; a National Insti-
tutes of Health Stroke Scale (NIHSS)5 of 4 to 15 with a score of 
2 or more in the limb motor items persisting beyond 48 hours 
but within 7 days of onset of stroke and availability for follow-
ups. In addition to conventional rehabilitation, patients were 
randomly assigned to one of the three treatment regimens: High 
dose group received active herbal preparation TCM for 8 weeks; 
Low dose group received active herbal preparation for 4 weeks, 
followed by placebo preparation for 4 weeks, and placebo group 
received placebo for 8 weeks. The primary outcome was mRS 
grade at month 3, defined as a good outcome with a mRS ≤2. 
Secondary outcomes were the scores of NIHSS, Barthel Index 
and Mini Mental State Examination (MMSE) at month 3 and 
Journal of Stroke  2016;18(3):361-363
http://dx.doi.org/10.5853/jos.2016.00962
Cheung, et al. Herbs Trial in Hong Kong
http://dx.doi.org/10.5853/jos.2016.00962362 http://j-stroke.org
month 6, and mRS at month 6. 
Group differences for continuous data and non-normally dis-
tributed data were examined by ANOVA test or Kruskal–Wallis 
test, respectively. Intention-to-treat analysis was performed in 
all randomized patients. All statistical analysis was performed 
with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Differences 
with P<0.05 were considered significant.
Of the randomized 198 patients, totally 24 patients were lost 
to follow-up at month 3. Therefore, 174 patients (87.9%) were 
included the intention-to-treat analysis (60 patients with high 
dose TCM, and 57 with low dose TCM and placebo, respectively). 
The groups were balanced in most demographic data except the 
prevalence of ischemic heart disease (P=0.024). The proportion 
of patients with mRS ≤2 at month 3 was 73.3% in the TCM 
group and 66.7% in the placebo group as shown in Table 1 (ab-
solute risk reduction 6.6%, P=0.434). There were no significant 
differences in the secondary outcomes, the mortality rate, the 
occurrence of vascular events by 6 months (recurrent stroke, 
acute coronary syndrome, deep vein thrombosis and hemorrhag-
ic transformation or intracerebral hemorrhage), adverse events, 
or severe adverse events across the groups (Table 1, all P>0.05). 
Our study showed a favorable trend that 73.3% of patients in 
the herbal formula group had good outcomes at 3 months after 
stroke onset, which was slightly higher than those in the placebo 
group. The favorable trend might warrant further investigation 
into the use of this herbal formula for ischemic stroke rehabilita-
tion. Additionally, the results showed a very good safety profile 
for the use of herbal formula. Overall the treatment was very 
well tolerated and none of the adverse events were considered 
drug-related.
Currently, there are more than 100 TCM agents used clinically 
in China for stroke with the approval of the Chinese National 
Drug Administration.6 However, there is a lack of availability of 
the evidence for the efficacy and safety of TCM. A recent meta-
analysis6 of TCM for ischemic stroke found only 3 studies were 
randomized, double-blind, and placebo-controlled, and only 2 
studies had long-term outcome assessment. In Asia, a double-
blind, placebo-controlled, randomized, multi-center study to in-
vestigate Chinese medicine Neuroaid efficacy on stroke recovery 
(CHIMES Study) is ongoing to test whether Neuroaid is superior 
to placebo in reducing neurological deficit and improving func-
tional outcome in patients with acute cerebral infarction of an 
intermediate severity.7 The sub-study of CHIMES confirmed the 
safety of Neuroaid in acute stroke patients receiving a 3-month 
treatment.8 Different from TCM used in previous studies, we de-
veloped an innovative herbal formula with 7 components, in 
which Huangqi and Danshen are the main ingredients. Regard-
ing the underlying mechanisms of TCM in post-stroke recovery, 
it may be attributed to antioxidant, anti-inflammatory, and anti-
glutamate effects of TCM,9 which could dilate blood vessels, sup-
Table 1. Primary outcome, secondary outcomes and mortality, adverse events and severe adverse events in each group
 
8 weeks TCM 
(n=60)
4 weeks TCM+4 weeks 
Placebo (n=57)
8 weeks Placebo 
(n=57)
P
Primary outcome
mRS ≤2 at 3 months 44 (73.3%) 36 (63.2%) 38 (66.7%) 0.434
Secondary outcome
mRS ≤2 at 6 months 44 (73.3%) 40 (70.2%) 36 (63.2%) 0.439
NIHSS at 3 months 3.0 (1.8-4.3) 3.0 (1.0-5.0) 3.0 (1.0-5.0) 0.846
NIHSS at 6 months 2.0 (1.0-4.0) 3.0 (2.0-5.0) 3.0 (1.8-5.0) 0.331
BI at 3 months 95.0 (85.0-100.0) 95.0 (65.0-100.0) 95.0 (75.0-100.0) 0.413
BI at 6 months 100.0 (85.0-100.0) 95.0 (75.0-100.0) 100.0 (85.0-100.0) 0.713
MMSE at 3 months 26.0 (23.0-28.0) 25.0 (22.0-29.5) 26.0 (21.0-29.0) 0.838
MMSE at 6 months 27.0 (24.0-29.0) 26.0 (21.5-29.0) 25.5 (21.3-30.0) 0.333
Mortality
  3 months 2 (3.3%) 0 (0.0%) 1 (1.8%) 0.502
  6 months 4 (6.7%) 0 (0.0%) 2 (3.5%) 0.366
Vascular events at 6 months
   Recurrent stroke 2 (3.3%) 2 (3.5%) 4 (7.0%) 0.347
   Acute coronary syndrome 1 (1.7%) 2 (3.5%) 0 (0.0%) 0.502
   Deep vein thrombosis 0 (0.0%) 1 (1.8%) 0 (0.0%) 0.983
   Haemorrhagic transformation or  
      intracerebral hemorrhage
1 (1.7%) 1 (1.8%) 0 (0.0%) 0.404
Adverse event 26 (43.3%) 31 (54.4%) 25 (43.9%) 0.939
   Severe adverse events 14 (23.3%) 11 (19.3%) 9 (15.8%) 0.305
mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; BI, Barthel Index; MMSE, mini Mental State Examination; TCM, Traditional 
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press platelet aggregation, protect against ischemic reperfusion 
injury, and enhance the tolerance of ischemic tissue to hypoxia.10
Our study had the limitation of having a small sample size, 
which may lead the non-significant difference on the efficacy of 
the herbal formula in post-stroke recovery treatment. Neverthe-
less, our study’s strength is that some favorable trends were ob-
served and results provided estimates for sample size require-
ments to achieve statistical significance in future large-scale 
clinical studies.
In conclusion, the innovative herbal formula for 8-week medi-
cation did not statistically significantly facilitate neurological re-
covery in ischemic stroke beyond 48 hours but within 7 days of 
onset. However, some favorable trend could be noted on the 
mRS score in the herbal formal group versus the placebo, which 
probably need a large phase III trial to confirm the preliminary 
findings. 
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